The partnership brings together two highly complementary capabilities. 3D CoSeedis in chip Technology Organoid Models will be analyzed with Next-Generation Metabolomics, lipidomics, and proteomics incorporating advanced computational processing and interpretation. This will provide deeper physiological insights and biomarker discovery opportunities from studies conducted using 3D CoSeedis Multi-Organoid disease models.

Combining Human-Relevant Biology with Comprehensive Multi-Omics Discovery
As the life sciences industry increasingly adopts New Approach Methodologies (NAMs) and seeks more predictive alternatives to traditional preclinical models, drug developers require both physiologically relevant test systems and comprehensive analytical tools capable of generating actionable biological insights. The collaboration directly addresses this need by integrating abc biopply's standardized humanized in chip technology platform with Panome Bio's advanced untargeted metabolomics, proteomics, transcriptomics, and integrated multi-omics capabilities.

abc biopply's proprietary 3D CoSeedis in chip Technology enables the generation of scalable and standardized humanized multi-organoid disease models designed to enhance physiological relevance and improve translational predictability in drug development. Panome Bio complements these capabilities with its truly untargeted LC/MS-based discovery platforms, integrated multi-omics capabilities, and reference database of 285,000 compounds that allow researchers to identify biomarkers, mechanistic pathways, and characterize treatment responses.

The collaboration will provide clients of both organizations with broader access to fit-for-purpose solutions that combine functional efficacy and toxicity testing with deep molecular characterization, enabling more informed development decisions earlier in the drug discovery process. The companies believe that combining standardized organoid biology with comprehensive multi-omics analysis has the potential to improve biomarker identification, mechanism-of-action studies, patient stratification efforts, and translational research programs across multiple therapeutic areas.

Arne Faisst, Founder and CEO of abc biopply AG, commented: "The future of preclinical development lies in generating data that is both biologically relevant and mechanistically informative. By integrating Panome Bio's industry-leading multi-omics capabilities into our preclinical study services, we enable our customers to go beyond traditional efficacy and toxicity readouts and gain a much deeper understanding of disease biology and therapeutic response.

Dr. Edward Weinstein, CEO and Co-Founder of Panome Bio, added: "High-quality omics data begins with high-quality biology. abc biopply has developed a unique platform of standardized humanized multi-organoid models that offers an outstanding opportunity to generate molecular datasets with enhanced biological relevance and reproducibility. By combining our next-generation multi-omics capabilities with abc biopply's advanced organoid platform, we believe we can help drug development uncover deeper biological insights and accelerate the development of new therapies."